Pfizer's stock is down roughly 60% from its late 2021 highs, but the drug giant is working to innovate its way back into the ...

Pfizer Inc. (NYSE:PFE) is included among the 14 Best Pharma Dividend Stocks to Buy in 2026. On December 16, Pfizer Inc. (NYSE ...

The market of 2025 will be remembered for its extremes. While investors poured billions into technology sector giants and ...

We regret to report that long term Pfizer Inc. (NYSE:PFE) shareholders have had that experience, with the share price ...

Pfizer Inc (NYSE:PFE) maintains global operations across medicines and vaccines, delivering consistent earnings, operational ...

TD Cowen analyst Steve Scala maintained a Hold rating on Pfizer today and set a price target of $30.00. According to TipRanks, Scala is a 4-star analyst with an average return of 11.3% and a 64.82% ...

The stock's Price to Earnings ratio of 14.56 is lower than the industry average by 0.24x, suggesting potential value in the ...

Pfizer Inc. (NYSE:PFE)’s shares are down by 5.90% year-to-date, and December has been a tumultuous month for them.

Pfizer is a $145 billion pharmaceutical industry giant with a long history of success behind it. Wall Street bid the stock up during the COVID-19 pandemic, but now investors have soured on the shares.

Pfizer disclosed a patient death in a marstacimab hemophilia study, triggering a safety review and reassessment of surgical ...

Pfizer (NYSE:PFE) and GlaxoSmithKline (NYSE:GSK) are among the top drugmakers planning price increases for hundreds of ...

Investing.com -- A patient died after receiving Pfizer Inc.’s (NYSE:PFE) hemophilia drug Hympavzi, adding to challenges for ...